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Key Points
• Phenotypic and genotypic
profiling of MDM2 in DLBCL.
• MDM2 as a negative regulator
of p53 tumor suppressor
function.
MDM2 is a key negative regulator of the tumor suppressor p53, however, the prognostic
significance of MDM2 overexpression in diffuse large B-cell lymphoma (DLBCL) has not
been defined convincingly. In a p53 genetically–defined large cohort of de novo DLBCL
patients treated with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine,
and prednisone (R-CHOP) chemotherapy, we assessed MDM2 and p53 expression by
immunohistochemistry (n 5 478), MDM2 gene amplification by fluorescence in situ
hybridization (n 5 364), and a single nucleotide polymorphism in the MDM2 promoter,
SNP309, by SNP genotyping assay (n 5 108). Our results show that MDM2 overex-
pression, unlike p53 overexpression, is not a significant prognostic factor in overall DLBCL. Both MDM2 and p53 overexpression
do not predict for an adverse clinical outcome in patients with wild-type p53 but predicts for significantly poorer survival in patients
with mutated p53. Variable p53 activities may ultimately determine the survival differences, as suggested by the gene expression
profiling analysis. MDM2 amplification was observed in 3 of 364 (0.8%) patients with high MDM2 expression. The presence of SNP309
did not correlate with MDM2 expression and survival. This study indicates that evaluation of MDM2 and p53 expression correlating
with TP53 genetic status is essential to assess their prognostic significance and is important for designing therapeutic strategies
that target the MDM2-p53 interaction. (Blood. 2013;122(15):2630-2640)
Introduction
MDM2/Hdm2, the human homolog of murine double minute
2 (Mdm2) or p53 E3 ubiquitin protein ligase homolog (mouse)
(Homo sapiens), is a key negative regulator of the tumor suppressor
p531 and has other p53-independent functions.2 The MDM2 gene
is transactivated by p53, and thus p53 degradation by MDM2 forms
the other direction of a negative-feedback loop. MDM2 is frequently
overexpressed in cancer, but its prognostic importance has been
elusive in many disease entities.3 MDM2 overexpression has been
shown to facilitate B-cell lymphomagenesis in vivo4 and to inactivate
the tumor suppressor function of wild-type p53 (WT-p53) in vitro.5
MDM2 overexpression, however, has correlated inconsistently with
adverse clinical outcomes in patients with hematologic malignancies.6,7
Several factors could account for the inconsistent results:
(1) Small study sizes; (2) different cutoffs for MDM2 expression;
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(3) unclear expression and function of MDM2 isoforms8; and
(4) posttranslational modiﬁcations or subcellular localization of
MDM2.3 In stress conditions, both p53 and MDM2 are modiﬁed
(eg, phosphorylation by ATM), resulting in reduced afﬁnity and
increased degradation of MDM2.9 In addition, MDM2 nuclear
entry is inhibited via induction of p53-responsive PTEN,10 and
p53-inducible p21 maintains another positive feedback loop.11 A ﬁfth
possible factor is oscillation of the p53-MDM2 autoregulatory
feedback loop (Figure 1C), which has not been recognized by the
previous prognostic studies. Elegant models and laboratory observa-
tions have shown that cellular levels of WT-p53 and MDM2 ﬂuctuate
in an oscillatory fashion in response to stress, such as DNA damage,
hypoxia, or oncogene activation, and that the numbers of pulses
and the fraction of cells with oscillatory pulses increase with the
strength of DNA damage.9-23 The oscillatory kinetics and the variable
amplitude of p53/MDM2 pulses over cell population may affect
the measurement of MDM2 expression using immunohistochem-
istry (IHC), a commonly used method in clinical diagnostic and
prognostic studies. If the study cohort is too small, or the cutoff is
inappropriately established, the survival difference between 2 groups
may not be truly reﬂected. To obtain evaluable results beyond the
“noise” caused by oscillation, a large cohort of cases is essential.
In comparison, MDM2 function toward mutant p53 (MUT-p53)
and the kinetics of MDM2 and MUT-p53 levels under stress are
not well deﬁned. In a mouse model, MDM2 and DNA damage
regulate MUT-p53 levels in a manner similar to WT-p53.24 However,
most MUT-p53s have lost the ability to transactivate MDM2, so
basal MDM2 levels cannot compensate for increased MUT-p53
because of the sustained stress.24 Conversely, in a panel of cell
lines, mutual stabilization of MDM2 (increased half-life time from
30 minutes to 2 hours) and MUT-p53 was observed.25
The prognostic signiﬁcance of MDM2 expression is further
complicated by other nononcogenic functions of MDM2. MDM2
monoubiquitinates p53, leading to only nuclear export and not p53
degradation.12 MDM2 promotes p53 translation by binding to p53
mRNA, simultaneously impairing its E3 ligase activity.26 After
exposure to the p53-activating drug RITA, MDM2 can enhance the
apoptotic response induced by p53 through downregulation of p21
(cell-cycle inhibitor) at both the transcriptional and posttranscrip-
tional levels.27 In normal human or murine cells, MDM2 induces
G0/G1 cell-cycle arrest.28 These MDM2 functions suggest that MDM2
expression can be a positive prognostic factor in certain cellular
contexts. In mouse models, Mdm2 appeared to be both a tumor
suppressor and an oncoprotein depending on its cellular levels.29
Mdm2 exerts p53-independent tumorigenesis in mouse models,
but the mechanisms are unclear,29,30 although several proteins
(such as p73, p63, RB, Sp1, E2F1, L5) have been identiﬁed to have
interaction with MDM2.2 However, the principal role of Mdm2 as
a negative p53 regulator is supported by the similar survival curves
and tumor spectrum of p532/2Mdm22/2Mdm42/2 and p532/2mice,31
or the similar tumor incidence in p532/2Mdm22/2 and p532/2
mice.29 On the other hand, few p53-independent mechanisms
upregulating MDM2 are known.12 In many tumors, MDM2
overexpression is not caused by gene ampliﬁcation. The single
nucleotide polymorphism (SNP) 309 T→G in the MDM2 promoter
is associated with an increased afﬁnity with the transcriptional
Figure 1. MDM2 and p53 expression in DLBCL patients treated with R-CHOP. (A-B) Histogram showing the distribution of MDM2 and p53 expression levels in the DLBCL
cohort. X-axis, percentage of immunopositive cells in tumors; Y-axis, numbers of DLBCL patients. (C) Illustration of p53 and MDM2 kinetic pulses in tumor cells under stress
conditions. In a single cell, because of the fluctuating p53/MDM2 levels in oscillatory pulses, the IHC pattern is (1) p53–/MDM2– at zero time point A or E after cellular stress is
removed; (2) p531/MDM21 at time point B; (3) p53–/MDM21 at time point C; and (4) p531/MDM2– at time point D. Same patterns over cell population may be generated by
evaluation of the percentage of MDM21 cells and defining overexpression by certain cutoffs. (D) Representative MDM2 immunohistochemical staining patterns.
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activator Sp1, resulting in elevated MDM2 expression, in a gender-
speciﬁc (females) and hormonal-dependent manner.32,33 On the
other hand, in Burkitt lymphoma cells, MDM2 overexpression was
caused by enhanced translation.5
To explore the prognostic signiﬁcance of MDM2 expression
and mechanisms of MDM2 overexpression, and to recognize
the possible factors that could complicate the analysis of the
results, we assessed for MDM2 expression, MDM2 ampliﬁcation
and polymorphism, p53 expression, and TP53 genetic status in
a large cohort of patients with diffuse large B-cell lymphoma
(DLBCL).
Materials and methods
Patients
The initial study cohort consisted of 478 de novo DLBCL patients treated
with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and
prednisone (R-CHOP) therapy in 29 medical centers. The diagnostic criteria,
review process, treatment regimens, treatment response criteria, and eligibility/
exclusion criteria have been described previously.34,35 At last follow-up, 36%
(173/478) of the patients had died. The median follow-up interval for the
305 censored patients was 56.5 months (range, 12.0-180.3). The validation
set consisted of another 227 DLBCL patients with similar clinical features
and treatment regimens. This study was approved as being of minimal to no
risk or as exempt by the Institutional Review Boards of all participating
centers, and at The University of Texas MD Anderson Cancer Center. This
study was conducted in accordance with the Declaration of Helsinki.
p53 and MDM2 immunohistochemical staining
Biopsy samples obtained at diagnosis were ﬁxed in formalin and embedded
in parafﬁn, and tissue microarrays (TMAs) were constructed using tissue
array (Beecher Instruments, Silver Spring, MD).36 IHC was performed
on TMAs using antibodies DO-7 for p53 (Dako) and IF2 for MDM2
(N-terminal37) (Calbiochem, Billerica, MA), as described previously.34,36
Expression levels of p53 and MDM2 for each sample were determined by
counting the percentage of positive cells in TMA cores, in combination
with the assessment of intensity. Each TMA core contained approxi-
mately 500 tumor cells. Six pathologists in addition to the pathologist at
each contributing medical center independently evaluated the tissue cores
by light microscopy for p53 and MDM2 expression without knowledge of
the clinical outcomes. Discrepancies were resolved by joint review on
a multihead microscope.
TP53 mutations and SNP309 genotyping of MDM2
p53 mutation status was determined by resequencing microarray using
p53 AmpliChip (Roche Molecular Systems, Pleasanton, CA), as described
previously.34
The SNP309 (rs2279744) status of the MDM2 promoter, was determined
by using a Taqman SNP genotyping assay, as previously described.32 Primers
were purchased from Applied Biosystems (Foster City, CA).
Gene expression profiling
Gene expression proﬁling (GEP) was performed using Affymetrix GeneChip
Human Genome HG-U133 Plus 2.0 chips.36 The GEO accession number is
GSE#31312. Normalized microarray data were analyzed for differential
expression between MDM21 and MDM2– patients, or p531 and p53–
patients with WT-p53 or MUT-p53. Univariate analysis was performed to
identify differentially expressed genes (DEGs) using the Student t test. The
P values obtained by multiple t tests were corrected for false discovery rate
(FDR) using the BUM method. DEGs were identiﬁed with P value cutoffs
of .0012 to .0035 for respective comparisons at an FDR of .30.
Fluorescence in situ hybridization for MDM2 gene
amplification analysis
A bacterial artiﬁcial chromosome clone (RP11-1064P9, obtained from the
BACPAC Resource Center of the Children’s Hospital Oakland Research
Institute, http://bacpac.chori.org/home.htm) localized on chromosomal
region 12q13-15 was used as a probe for MDM2 ﬂuorescence in situ
hybridization (FISH) and labeled with Spectrum Orange. A control region
from the centromere of chromosome 12 was used as a ploidy reference and
labeled with Spectrum Green. Dual-color FISH was performed in 4 micron
sections of the TMAs. Images were captured and archived using Cytovision
software (Applied Imaging, Santa Clara, CA). Fluorescence signals were
scored by 2 independent investigators by counting the number of MDM2
and reference probe signals in 150 to 250 well-deﬁned nuclei. A sample was
scored as ampliﬁed when the ratio between the test and control signals was.2.
Statistical analysis
Clinical and laboratory features at the time of presentation between different
DLBCL subgroups were compared using the x2 test. Overall survival (OS)
was calculated from the time of diagnosis to the time of death from any
cause. Progression-free survival (PFS) was calculated from the time of
diagnosis to the time of progression or death from any cause.35 Patients who
remained alive or were progression-free were censored at the last follow-up.
Univariate and multivariate analyses for survival of the study cohort were
performed with IBM SPSS statistics 19.0 (Armonk, NY) using the Cox
proportional hazards regression model and the forward-stepwise method.
OS and PFS curves of different groups were analyzed by GraphPad Prism 5
software using the Kaplan-Meier method, and differences were compared
using the log-rank (Mantel-Cox) test. All differences with P < .05 were
considered to be statistically signiﬁcant.
Results
MDM2 and p53 expression
Our results showed variable p53/MDM2 levels (0-100%) among
478 patients and all combinations of IHC staining patterns (1/1,
1/2, 2/2, 2/1) (Table 1A-B), which could possibly be explained
by the oscillations of p53/MDM2 levels in patients with WT-p53
(Figure 1C) and other regulatory factors that affect p53 and
MDM2 levels. The mean percentage of MDM2-positive cells in
478 patients was 22%. The mean percentage of p53-positive cells
was 23% in 474 patients with p53 expression data available. Based
on occurrence distribution of different MDM2 or p53 expression
levels (Figure 1A-B), both MDM2 and p53 overexpression
(MDM21, p531) were deﬁned as .10% of cells positive for IHC
staining, which is similar to cutoffs used by others in earlier lymphoma
studies of MDM2 and p53 expression.6,38,39 Using the .10%
cutoff, 193 of 478 (40.4%) DLBCLs had MDM2 overexpression
and 182 of 474 (38.4%) DLBCLs had p53 overexpression. The
frequency of MDM2 overexpression was higher (but not signiﬁcant)
in DLBCLs with WT-p53 (41.9%, 156/372) than in DLBCLs with
MUT-p53 (34.9%, 37/106). Correspondingly, there is a higher mean
level of MDM2 expression in DLBCL patients with WT-p53 than
DLBCLs with MUT-p53 (24% vs 17%, Table 1A). Comparatively,
p53 overexpression is signiﬁcantly more common in DLBCLs with
MUT-p53 than with WT-p53 (71.4% vs 29.1%) (P, .0001, see case
numbers in Table 1A), and has a higher mean level of p53 expression
in DLBCL with MUT-p53 (54% vs 14%). MUT-p53 was over-
expressed compared with WT-p53 in both MDM2– and MDM21
DLBCLs (Table 1B), suggesting that overexpression was not readily
explained by reduction in MDM2-mediated degradation alone.
Also notable, all patients (n5 16) with non-sense, splice-site, or
frame-shift p53 mutations had a p53-negative immunophenotype; all
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but 4 patients were also MDM2–.3 In contrast, 84% of patients with
missense mutations had a p531 phenotype, and 72% of patients
had a high IHC score (>50%) of tumor cells (mean level, 64%).
MDM2 expression had no good correlation with missense-MUT-
p531 phenotype: p531/MDM2–: 52.7%; p531/MDM21: 30.8%;
p53–/MDM2–: 11.0%; p53–/MDM21: 5.5%.
Clinical features of the cohort and univariate and
multivariate analysis
Clinical features of the patients were compared between MDM2–
and MDM21 DLBCL in the entire cohort and in subcohorts of
patients with WT- or MUT-p53 (Table 2A).
Univariate analysis regarding survival indicated that an Inter-
national Prognostic Index (IPI) score of .2 and the 5 risk factors
composing the IPI (age, stage, serum lactate dehydrogenase level,
performance status, extranodal sites), as well as B-symptoms, tumor
size, TP53 mutation, and p53 overexpression, were signiﬁcantly
associated with poorer survival. MDM2 overexpression was not
associated with poorer survival.
The prognostic factors according to univariate analysis, and
MDM2 .10% and gender that are signiﬁcantly different between
MDM21 and MDM2– DLBCLs (Table 2A), were then entered into
multivariate survival analysis. The IPI .2, TP53 mutations, and
B-symptoms remained as the independent prognostic factors, whereas
p53 .10% and MDM2 .10%, tumor size .5 cm, and gender were
not associated with signiﬁcantly poorer survival (Table 2B).
However, in the MUT-p53 subcohort, the IPI .2, p53 .10%,
and MDM2 .10% remained prognostically signiﬁcant in the multi-
variate analysis, whereas B-symptoms and tumor size .5 cm did
not independently predict a poorer prognosis (Table 2B).
Prognostic significance of MDM2 and p53 overexpression
MDM2 overexpression was not signiﬁcantly associated with poorer
survival for the entire cohort (P values: .18 for OS and .41 for PFS;
Figures 2A and 3A), or within patients with WT-p53 (P values:
.71 for OS and .99 for PFS; Figures 2C and 3C). However, MDM2
overexpression conferred an inferior OS for patients with MUT-p53
(median OS: 30.0 vs 87.3 months; hazard ratio [HR] 5 2.92; 95%
conﬁdence interval [CI], 2.33-3.50; P 5 .0072) (Figure 2E). A
similar trend was observed for PFS curves (Figure 3E).
In contrast, p53 overexpression correlated with poorer survival
for the entire cohort (P 5 .017 for OS, and P 5 .019 for PFS).
However, the prognostic signiﬁcance of p53 overexpression was
restricted to DLBCL patients with MUT-p53 (median OS: 33.3 vs
82.4 months; HR5 2.48; 95% CI, 2.0-2.96; P5 .016; median PFS:
25.8 vs 82.4 months; HR 5 2.16; 95% CI, 1.23-3.79; P 5 .0073)
(Figures 2 and 3B,D,F).
The prognostic signiﬁcance of MDM2 or p53 overexpression is
conﬁrmed in the validation set (supplemental Figure 1).
Concurrent evaluation of p53 and MDM2 expression
Not only the survival curves for p53 and MDM2 overexpression
showed similar patterns in the WT-p53 and MUT-p53 subgroups
(Figures 2 and 3C-F): patients with p531/MDM22, p53–/MDM21,
or p531/MDM21 had comparable survival rates (Figure 4A-D),
reinforcing the idea that MDM21 and p531 patients are prognostic
equivalents in the WT- or MUT-p53 subgroups. If stratifying patients
with either MDM2 or p53 overexpression as a single group, the
impact of their overexpression on survival was similar to that of
p53 overexpression (Figure 4E-F for the MUT-p53 subgroup).
Differentially expressed genes
DEGs were identiﬁed by comparing GEPs of different groups:
MDM21 vs MDM2– DLBCLs with WT-p53 (DEGs1: 157) or
MUT-p53 (DEGs2: 302), as well as p531 vs p53– DLBCLs with
WT-p53 (DEGs3: 547) or MUT-p53 (DEGs4: 0) (Figure 5A-C).
Although DEGs1 and DEGs2 shared 11 genes (supplemental Table 1),
they appeared to be p53- and MDM2-independent, suggesting the
different and heterogeneous transcription programs in the MUT-p53
subgroup. Common 49 genes (supplemental Table 2) between DEGs1
and DEGs3 include CDKN1A/p21, MDM2, MDM4, and ATM.
Albeit the stress transmitter and p53 activator, ATM was down-
regulated both in MDM21 and p531 DLBCLs with WT-p53,
probably by p53-inducible Wip1.12 Only one gene (probable ATP-
dependent RNA helicase DDX59) overlaps DEGs2 and DEGs3.
To identify genes and pathways responsible for the different
clinical outcomes of MDM21 vs MDM2– DLBCL patients with
MUT-p53, DEGs2 with fold change .2 were examined (supplemen-
tal Table 3). In MDM21 DLBCL patients, 8 genes with known
function (http://www.uniprot.org) were expressed at signiﬁcantly
higher levels (1.66- to 2.64-fold change, P , .0023), whereas 21
genes were expressed at signiﬁcantly lower levels (1.66- to 2.46-
fold change, P , .0023). None of these genes has been reported
to interact with MDM2, but CXCL5,40 MBD4,41 PAK2, ATG7,42
and DCUN1D143 have been reported to interact with the TP53
pathway, and many genes downregulated in MDM21 patients are
related to DNA repair or cell death. Upregulation of CXCL5 suggests
gain-of-function of MUT-p53s in MDM21 DLBCL,40 whereas
downregulated MBD4, PAK2, ATG7, and DCUN1D1 in MDM21
DLBCL suggest loss-of-function of MUT-p53s. Interestingly, not
all upregulated genes in patients with MDM21DLBCL are oncogenic
(such as MAD/MXD1 antagonizing MYC function), and there are
several oncogenes downregulated in MDM21 DLBCLs (such as
ATAD2 and DCUN1D1). When we further compared the GEPs
of MDM21 DLBCLs with WT-p53 vs MDM21 DLBCLs with
Table 1. MDM2 and p53 expression in DLBCL patients treated with
R-CHOP
A. MDM2 and p53 expression in DLBCL patients with WT-p53 or
MUT-p53
Overall WT-p53 MUT-p53
Number of MDM2– patients 285 216 69
Number of MDM21 patients 193 156 37
Mean MDM2 expression (% cells) 22% 24% 17%
Number of p53– patients 292 262 30
Number of p531 patients 182 107 75
Mean p53 expression (% cells) 23% 14% 54%
B. MDM2 and p53 expression in DLBCL patients with or without p53
overexpression
p531 p53– Mean p53 expression (% cells)
MDM2– patients 79 204 19%
WT-p53/MDM2– 32 183 9%
MUT-p53/MDM2– 47 21 39%
MDM21 patients 103 88 28%
WT-p53/MDM21 75 79 17%
MUT-p53/MDM21 28 9 50%
C. Numbers of DLBCL patients with different SNP309 genotypes
and the mean MDM2 expression level
Genotype Number of patients Mean MDM2 expression
G/G 10 33%
G/T 57 42%
T/T 41 42%
BLOOD, 10 OCTOBER 2013 x VOLUME 122, NUMBER 15 MDM2 PHENOTYPIC AND GENOTYPIC PROFILING IN DLBCL 2633
For personal use only.on February 13, 2017. by guest  www.bloodjournal.orgFrom 
MUT-p53, only 14 transcripts were signiﬁcantly differentially
expressed (P cutoff: .000113; FDR: .30), which appears to indicate
the simultaneous presence of WT-p53 transcription activities in some
MDM21 patients with MUT-p53.
MDM2 amplification
MDM2 ampliﬁcation was identiﬁed by FISH (Figure 5D) in 3 of
364 patients (0.8%). All 3 patients had strongly MDM21 tumors
(100%, 95%, and 60%). The 2 patients with 100% and 95% tumor
cells expressing MDM2 had WT-p53, and the patient with 60%
MDM21 cells had MUT-p53. These tumors had 90%, 70%, and 0%
p53-positive cells, respectively. All 3 patients were alive and censored
at last follow-up.
MDM2 SNP309 polymorphism and survival
SNP309 genotyping was analyzed in 108 patients treated with
R-CHOP. Clinical features of patients with homogenous T/T
genotype vs with T→G polymorphism were compared (Table 2A).
The only signiﬁcantly different variant is the number of extranodal
sites. Most female patients were elderly. In this cohort, no signiﬁcant
difference in the mean MDM2 expression levels was detected in
patients with different SNP309 genotypes (Table 1C).
Table 2. Clinical characteristics of 478 de novo DLBCL and multivariate survival analysis
A. Clinical characteristics of patients with de novo DLBCL treated with R-CHOP: comparison between patients with or without MDM2
overexpression or with different SNP309 genotypes
Overall (n 5 478) WT-p53 (n 5 372) MUT-p53 (n 5 106) SNP (n 5 108)
MDM2– MDM21 P MDM2– MDM21 P MDM2– MDM21 P T/T T/G or G/G P
n 285 193 216 156 69 37 41 67
Age, y
,60 124 68 95 56 29 12 17 22
$60 161 125 .07 121 100 .12 40 25 .33 24 45 .37
Gender
F 128 69 97 57 31 12 10 23
M 157 124 .046 119 99 .11 38 25 .21 31 44 .28
Stage
I-II 136 79 101 67 35 12 17 25
III-IV 137 108 .11 103 83 .37 34 25 .071 24 49 .41
B-symptoms
No 158 123 118 101 40 22 26 45
Yes 80 51 .35 63 40 .22 17 11 .73 12 18 .75
LDH
Normal 83 64 69 52 14 12 14 19
Elevated 180 103 .17 130 80 .50 50 23 .23 18 30 .82
No. of extranodal sites
0-1 217 138 164 111 53 27 41 52
$2 55 45 .27 41 36 .31 14 9 .63 0 15 .0011
Performance status
0-1 218 137 163 108 55 29 28 47
$2 30 27 .21 23 23 .20 7 4 .90 5 8 .94
Size of largest tumor
,5 cm 131 87 101 75 30 12 22 33
$5 cm 88 62 .78 63 45 .88 25 17 .25 8 18 .42
IPI risk group
0-2 170 99 130 78 40 21 25 36
3-5 83 71 .064 61 57 .062 22 14 .67 10 20 .50
Therapy response
CR 225 139 .081 176 123 .53 49 16 .0051 28 49 .59
PR 33 30 22 20 11 10 7 9
SD 13 4 8 3 5 1 1 1
PD 14 20 10 10 4 10 5 8
B. Multivariate survival analysis
OS PFS
Hazard ratio 95% CI P value Hazard ratio 95% CI P value
Overall cohort
IPI .2 3.04 1.96-3.96 ,.0001 2.59 1.8-3.62 ,.0001
B-symptoms 1.43 1.00-2.04 .048 1.49 1.06-2.10 .024
TP53 mutation 1.59 1.06-2.26 .013 1.52 1.03-2.17 .023
MUT-p53 subcohort
IPI .2 2.03 1.05-3.93 .035 1.95 1.02-3.74 .042
p53 .10% 2.70 1.04-7.04 .042 2.87 1.10-7.45 .031
MDM2 .10% 2.24 1.17-4.27 .015 1.96 1.03-3.70 .041
LDH, lactate dehydrogenase; CR, complete remission; PR, partial response; SD, stable disease; PD, progressive disease.
For therapy response, we calculated P values as CR vs other responses. Some clinical features of certain cases were not available.
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OS and PFS were compared among patients with G/G (n5 10),
G/T (n 5 57), and T/T (n 5 41) genotypes. The SNP309 T→G
change did not correlate with poorer survival in DLBCL patients
(Figure 5E-F).
Discussion
In contrast with several reports in the literature for other types
of human cancer, we show in DLBCL patients that MDM2 overex-
pression has no signiﬁcant (P . .05) adverse impact on survival in
the entire cohort (Figures 2 and 3A) and in the WT-p53 subcohort
(Figures 2C and 3C) with a .10% cutoff or with other cutoffs of
20% to 70%, suggesting that suppression of p53 by MDM2 in tumor
cells did not signiﬁcantly affect WT-p53 function under stress
conditions. Possible explanations include: (1) Posttranslational
modiﬁcations of p53 and MDM2 resulted in reduced repression by
MDM2, and more degradation of tumorigenic MDM29,28 rather
than degradation of p53; (2) interaction of p53/MDM2 can be
regulated by many other factors (eg, ARF, L11, MDM4)1; (3) during
the time delay of MDM2 repression, the tumor suppressor function
of WT-p53 is already exerted; and (4) other MDM2 functions
positive for the p53 function may also exist.26-28 Correspondingly,
MDM2 overexpression did not signiﬁcantly affect the clinical
outcomes of DLBCL patients with WT-p53 in our study, which
may explain why clinical trials of MDM2 inhibitors have not
shown impressive efﬁcacy.1
Similarly, p53 overexpression by IHC did not predict poorer
survival in patients with WT-p53 (Figures 2 and 3D). This is true
for cutoffs of 10% to 70%. Overexpression of WT-p53 in tumor
cells could be caused by high endogenous cellular stress (DNA
damage or oncogene activation), which increases the fraction of
cells with oscillatory p53/MDM2 pulses17 (only part of which were
detected by IHC). The correlation between levels of p53 reﬂecting
pretreatment cellular stress level and clinical outcomes was not
signiﬁcant, probably because after chemotherapy treatment, p53
would be activated to high levels as a result of the widespread
DNA damage rendered by chemotherapy or radiation. What deter-
mined the tumor cell fate and the therapeutic response depended on
whether p53 functions properly after the treatment, not the p53
expression level before treatment.
In contrast, in DLBCL patients with MUT-p53, p53 over-
expression correlated with signiﬁcantly worse survival (Figures 2
and 3F), which stayed signiﬁcant with cutoffs of 10% to 60%
(P values are marginal for 40-60%). Because all non-sense, splice-
site, and frame-shift p53 mutants had a p53-negative phenotype
(accounting for 53% of MUT-p53– cases) and MUT-p531 patients
carried exclusively missense mutants with probable dominant onco-
genic gain-of-function, the different prognosis of MUT-p531 and
MUT-p53– arms may be attributed to the variable loss-of-function
and gain-of-function of MUT-p53s.44 However, the survival dif-
ference between patients with missense p53 mutations and other
patients is not signiﬁcant. Moreover, after excluding other types of
p53 mutants, patients with missense p53 mutants were still stratiﬁed
into 2 groups, with signiﬁcant different survival according to p53
Figure 2. Impact of MDM2 and p53 expression
on OS in de novo DLBCL patients with WT- or
MUT-p53.
BLOOD, 10 OCTOBER 2013 x VOLUME 122, NUMBER 15 MDM2 PHENOTYPIC AND GENOTYPIC PROFILING IN DLBCL 2635
For personal use only.on February 13, 2017. by guest  www.bloodjournal.orgFrom 
overexpression or not before chemotherapy. In a mouse model,
MUT-p53 was stabilized by oncogene activation.45 Higher MUT-p53
expression levels at diagnosis may indicate higher DNA damage,
sustained oncogene activation, loss-of-function (including MDM2
activation), and gain-of-function of MUT-p53 at presentation; che-
motherapy probably further stabilized and increased the levels of
MUT-p5345 and added more DNA damage to tumor cells because
of the absence of WT-p53 function. Therefore, pretreatment MUT-
p53 expression level correlated with patient survival even after
chemotherapy.
Because MUT-p53s have oncogenic gain-of-function, the MDM2-
mediated degradation of MUT-p53 should alleviate oncogenesis.
Unexpectedly, overexpression of MDM2, which was thought to
regulate oncoprotein MUT-p53 in the same way as WT-p53
(MDM2 ┤p53),24 was also correlated with poor survival in our
MUT-p53 subcohort, mirroring p53 overexpression (Figures 2
and 3E). To explain this observation, it may be that the impact of
MDM2 ┤MUT-p53 on p53 function was simply not as signiﬁcant
as MDM2 ┤WT-p53, or MDM2 ┤MUT-p53 was lost in MUT-p53
DLBCL.46 However, none of the MUT-p53s in our study had
mutations in the MDM2-binding domain (N-terminus)46; most
MUT-p53s had mutations in the DNA-binding domain (DBD),34
which may have altered conformation and interaction with MDM2
by other sites alternative to the N-terminus, yet could have still been
efﬁciently degraded by MDM2 through a pathway different from
WT-p53.47 Conversely, it has been reported in cell lines that
MDM2 and MUT-p53 stabilize each other (p53→MDM2 and
MDM2→p53).25 Supporting this theory, coexistence of MDM2 and
MUT-p53 was observed in lung carcinomas, and the authors
speculated that this resulted in a gain-of-function phenotype, stabi-
lizing MDM2, which otherwise has a short half-life.37 Moreover,
MDM2 mRNA levels were not signiﬁcantly different between
MDM21 and MDM2– DLBCLs with MUT-p53, according to our
GEP analysis (Figure 5B; supplemental Table 3), suggesting that
MDM2 overexpression is caused by an increased stability at the
protein level.
Another explanation is the p53-independent oncogenic function
of MDM2.2,12 However, this idea is weakened by the fact that the
same effect was not shown in the WT-p53 subgroup. In addition,
none of the DEGs between MDM21 and MDM2– patients with
MUT-p53 have been found to relate to MDM2 (supplemental
Table 3). Instead, 5 genes are related to WT- or MUT-p53. Therefore,
it seems likely that the survival difference between MDM21 and
MDM2– patients can ultimately be attributed to the variable function
and activities of different MUT-p53s.44 In this setting, MDM2
expression should be evaluated concurrently with MUT-p53
expression for prognostic studies.
Stratiﬁcation by concomitant evaluation of p53 and MDM2
expression showed that MDM21 and p531 patients are prognostic
equivalents in WT- or MUT-p53 subgroups (Figure 4), supporting
the fact that MDM21 and p531 evaluation can be affected by the
oscillatory characteristics of p53/MDM2 levels, and that MDM2
overexpression may largely reﬂect p53 activity, an indication of
cellular stress in tumor cells, or the oncogenic activity of MUT-p53.
MDM2 overexpression potentially could be caused by MDM2
gene ampliﬁcation, enhanced transcription and translation, or
Figure 3. Impact of MDM2 and p53 expression
on PFS in de novo DLBCL patients with WT- or
MUT-p53.
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reduced degradation. MDM2 SNP309 T→G causes enhancedMDM2
transcription, resulting in attenuated p53 function.32,33 In our study,
MDM2 was rarely ampliﬁed. Similarly, increased MDM2 expression
was not shown in the homozygous (G/G) or heterozygous (G/T)
for SNP309 tumor cells among 108 patients in this study, and
SNP309 T→G did not correlate with signiﬁcantly poorer survival.
Although similar results have been shown in other reports,48,49
the lack of signiﬁcance may be attributable to a small number of
patients, similar estrogen levels in the SNP309 groups, oscillation
of MDM2 pulses, and the possibility that an endogenous MDM2
level could not be distinguished by IHC (which scores a fraction of
positive cells but not the intensity).
In our large DLBCL patient cohort, high MDM2 was not nec-
essarily associated with low p53 (64 of 157 MDM21 patients with
WT-p53 had p531 phenotype), p53 level could be high in patients
with WT-p53 (only ;44% of p531 patients had MUT-p53), and
expression of MDM2 and p53 mutations were not mutually exclusive
abnormalities of the TP53 pathway (Figure 2E; Table 1). These
observations may reﬂect the existence of oscillatory p53/MDM2
pulses in tumor cells or other regulatory factors that affect p53 and
MDM2 levels (eg, ARF, L11, MDM4, ATM, Akt, p300/CBP, p73).1,2
Nonetheless, several trends were observed by evaluating the mean
p53/MDM2 expression levels (Table 1). These trends suggest that
MDM2 was induced by WT-p53, whereas the WT-p53 level was
low because of the reduced cellular stress by WT-p53 function
and increased degradation by MDM2. In contrast, in patients with
MUT-p53, MDM2 level was not increased because of the loss-of-
function of MUT-p53 (according to the yeast p53-functional assay,50
Figure 4. Concurrent evaluation of p53 and MDM2 overexpression in DLBCL.
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only 4 MUT-p53s in MDM2– cases and 5 MUT-p53s in MDM21
cases of this study preserved function to transactivate MDM2);
MDM21 phenotype in 35% of MUT-p53 cases is likely caused
by enhanced stabilization (otherwise short half-life of MDM2) by
oncogenic activities of MUT-p53. MUT-p53 levels remained high
because of the sustained cellular stress, which activated and stabilized
MUT-p53 similarly to WT-p5345 and reduced degradation by
lower levels of MDM2 (Table 1B).
In conclusion, our results in R-CHOP–treated DLBCL patients
show that p53 or MDM2 overexpression predicts a signiﬁcantly
poor survival in patients with MUT-p53 but not in patients with
WT-p53. The prognostic value of p53 overexpression is attributable
to the poor prognosis of MUT-p531 but not WT-p531, and that
MUT-p53– patients were not necessary to have a poor survival.
Stratiﬁcation by p53 overexpression can be further improved by
concomitant evaluation of MDM2 expression. These ﬁndings may
explain the inconsistent prognostic value of p53 and MDM2 by
several previous reports in the literature and provide direction to the
future therapeutic drug designs targeting the p53-MDM2 pathway.
Acknowledgments
This work was supported by Harold C. and Mary L. Daily Endowment
Fellowships at The University of Texas MD Anderson Cancer
Figure 5. Comparison and characterization of differentially expressed genes in subgroups of DLBCL patients treated with R-CHOP. (A) DEGs in patients with
MDM21 and MDM2– DLBCL with WT-p53. (B) DEGs in patients with MDM21 and MDM2– DLBCL with MUT-p53. (C) DEGs in patients with p531 and p53– DLBCL with
WT-p53. (D) MDM2 amplification shown by FISH. In every single cell, the orange signals (MDM2), by at least two times, outnumber the green signals (centromere 12).
(E-F) Impact of MDM2 SNP309 on OS and PFS in DLBCL patients.
2638 XU-MONETTE et al BLOOD, 10 OCTOBER 2013 x VOLUME 122, NUMBER 15
For personal use only.on February 13, 2017. by guest  www.bloodjournal.orgFrom 
Center (Z.Y.X.M.); the Stiftung zur Krebsbekaempfung Zurich
Grant 269 award (A.T.); the Ministerio de Ciencia e Innovacio´n,
Spain (RETICC, SAF2008-03871) and the Spanish Association
against Cancer (AECC) (M.A.P.); National Cancer Institute and
National Institutes of Health grant 1R01CA160558 (W.H); a Univer-
sity of Texas MD Anderson Cancer Center Institutional Research
Grant Award, an Anderson Lymphoma Specialized Programs of
Research Excellence (SPORE) Research Development Program
Award, an Anderson Myeloma SPORE Research Development
Program Award, and Anderson Collaborative Research Funds with
High-Throughput Molecular Diagnostics and Roche Molecular
Systems (K.H.Y.). This work was also partially supported by the
National Cancer Institute and National Institutes of Health grants
(R01CA138688, 1RC1CA146299, P50CA136411, and P50CA142509)
and by the MD Anderson Cancer Center Support Grant CA016672.
Authorship
Contribution: Z.Y.X.-M. and K.H.Y. designed research; Z.Y.X.-M.
and K.H.Y. performed research; Z.Y.X.-M., M.B.M., A.T., S.M.-M.,
W.H., G.C.M., L.K., L.F., C.V., K.D., A.C., W.T., Y.Z., G.B., K.L.R.,
E.D.H., W.W.L.C., J.H.v.K., Q.H., J.H., W.A., M.P., A.J.M.F.,
J.N.W., L.W., X.Z., R.S.G., Y.L., M.A.P., L.J.M., and K.H.Y.
contributed vital new reagents, resources, and analytical tools under
approved IRB and MTA; Z.Y.X.-M., M.B.M., A.T., S.M.-M.,
C.V., K.D., A.C., Y.Z., G.B., K.L.R., E.D.H., W.W.L.C., X.Z.,
J.H.v.K., Q.H., J.H., M.P., A.J.M.F., J.N.W., X.Z., R.S.G., Y.L.,
M.A.P., and K.H.Y. collected clinical and follow-up data under
approved IRB and MTA; Z.Y.X.-M., M.B.M., A.T., S.M.-M., W.H.,
G.C.M., L.F., C.V., K.D., A.C., W.T., Y.Z., G.B., K.L.R., E.D.H.,
W.W.L.C., J.H.v.K., Q.H., J.H., W.A., M.P., A.J.M.F., J.N.W.,
L.W., X.Z., R.S.G., C.E.B.-R., S.A.W., Y.L., M.A.P., L.J.M.,
and K.H.Y. contributed vital strategies, participated in discussions,
and provided scientiﬁc input; Z.Y.X.-M. and K.H.Y. analyzed data;
Z.Y.X.-M. and K.H.Y. performed and supported statistical analysis;
and Z.Y.X.-M., L.J.M., and K.H.Y. wrote the paper.
Conﬂict-of-interest disclosure: The authors declare no compet-
ing ﬁnancial interests.
Correspondence: Ken H. Young, The University of Texas MD
Anderson Cancer Center, Department of Hematopathology, 1515
Holcombe Blvd, Houston, TX 77030-4009; e-mail: khyoung@
mdanderson.org; andMiguelA.Piris, ServiciodeAnatomiaPatologica,
Hospital Universitario Marques de Valdecilla Fundacion IFIMAV,
39008 Santander, Spain; e-mail: mapiris@humv.es.
References
1. Xu-Monette ZY, Medeiros LJ, Li Y, et al. Dysfunction
of the TP53 tumor suppressor gene in lymphoid
malignancies. Blood. 2012;119(16):3668-3683.
2. Iwakuma T, Lozano G. MDM2, an introduction.
Mol Cancer Res. 2003;1(14):993-1000.
3. Onel K, Cordon-Cardo C. MDM2 and prognosis.
Mol Cancer Res. 2004;2(1):1-8.
4. Wang P, Lushnikova T, Odvody J, Greiner TC,
Jones SN, Eischen CM. Elevated Mdm2
expression induces chromosomal instability and
confers a survival and growth advantage to
B cells. Oncogene. 2008;27(11):1590-1598.
5. Capoulade C, Bressac-de Paillerets B, Lefre`re I,
et al. Overexpression of MDM2, due to enhanced
translation, results in inactivation of wild-type p53 in
Burkitt’s lymphoma cells. Oncogene. 1998;16(12):
1603-1610.
6. Møller MB, Nielsen O, Pedersen NT. Oncoprotein
MDM2 overexpression is associated with poor
prognosis in distinct non-Hodgkin’s lymphoma
entities. Mod Pathol. 1999;12(11):1010-1016.
7. Solenthaler M, Matutes E, Brito-Babapulle V,
Morilla R, Catovsky D. p53 and mdm2 in mantle
cell lymphoma in leukemic phase. Haematologica.
2002;87(11):1141-1150.
8. Dang J, Kuo ML, Eischen CM, Stepanova L, Sherr
CJ, Roussel MF. The RING domain of Mdm2 can
inhibit cell proliferation. Cancer Res. 2002;62(4):
1222-1230.
9. Wagner J, Ma L, Rice JJ, Hu W, Levine AJ,
Stolovitzky GA. p53-Mdm2 loop controlled by
a balance of its feedback strength and effective
dampening using ATM and delayed feedback.
Syst Biol (Stevenage). 2005;152(3):109-118.
10. Ciliberto A, Novak B, Tyson JJ. Steady states and
oscillations in the p53/Mdm2 network. Cell Cycle.
2005;4(3):488-493.
11. Pang LY, Scott M, Hayward RL, et al. p21(WAF1)
is component of a positive feedback loop that
maintains the p53 transcriptional program. Cell
Cycle. 2011;10(6):932-950.
12. Marine JC, Lozano G. Mdm2-mediated
ubiquitylation: p53 and beyond. Cell Death Differ.
2010;17(1):93-102.
13. Lev Bar-Or R, Maya R, Segel LA, Alon U, Levine
AJ, Oren M. Generation of oscillations by the
p53-Mdm2 feedback loop: a theoretical and
experimental study. Proc Natl Acad Sci USA.
2000;97(21):11250-11255.
14. Monk NA. Oscillatory expression of Hes1, p53,
and NF-kappaB driven by transcriptional time
delays. Curr Biol. 2003;13(16):1409-1413.
15. Hamstra DA, Bhojani MS, Griffin LB, Laxman B,
Ross BD, Rehemtulla A. Real-time evaluation
of p53 oscillatory behavior in vivo using
bioluminescent imaging. Cancer Res. 2006;
66(15):7482-7489.
16. Lahav G, Rosenfeld N, Sigal A, et al. Dynamics of
the p53-Mdm2 feedback loop in individual cells.
Nat Genet. 2004;36(2):147-150.
17. Ma L, Wagner J, Rice JJ, Hu W, Levine AJ,
Stolovitzky GA. A plausible model for the digital
response of p53 to DNA damage. Proc Natl Acad
Sci USA. 2005;102(40):14266-14271.
18. Proctor CJ, Gray DA. Explaining oscillations and
variability in the p53-Mdm2 system. BMC Syst
Biol. 2008;2:75.
19. Geva-Zatorsky N, Rosenfeld N, Itzkovitz S, et al.
Oscillations and variability in the p53 system. Mol
Syst Biol. 2006;2:2006.0033.
20. Puszyn´ski K, Hat B, Lipniacki T. Oscillations
and bistability in the stochastic model of p53
regulation. J Theor Biol. 2008;254(2):452-465.
21. Hunziker A, Jensen MH, Krishna S.
Stress-specific response of the p53-Mdm2
feedback loop. BMC Syst Biol. 2010;4:94.
22. Ouattara DA, Abou-Jaoude´ W, Kaufman M. From
structure to dynamics: frequency tuning in the
p53-Mdm2 network. II Differential and stochastic
approaches. J Theor Biol. 2010;264(4):
1177-1189.
23. Kim DH, Rho K, Kim S. A theoretical model for
p53 dynamics: identifying optimal therapeutic
strategy for its activation and stabilization. Cell
Cycle. 2009;8(22):3707-3716.
24. Terzian T, Suh YA, Iwakuma T, et al. The inherent
instability of mutant p53 is alleviated by Mdm2 or
p16INK4a loss. Genes Dev. 2008;22(10):
1337-1344.
25. Peng Y, Chen L, Li C, Lu W, Agrawal S, Chen J.
Stabilization of the MDM2 oncoprotein by mutant
p53. J Biol Chem. 2001;276(9):6874-6878.
26. Candeias MM, Malbert-Colas L, Powell DJ, et al.
P53 mRNA controls p53 activity by managing
Mdm2 functions. Nat Cell Biol. 2008;10(9):
1098-1105.
27. Enge M, Bao W, Hedstro¨m E, Jackson SP,
Moumen A, Selivanova G. MDM2-dependent
downregulation of p21 and hnRNP K provides
a switch between apoptosis and growth arrest
induced by pharmacologically activated p53.
Cancer Cell. 2009;15(3):171-183.
28. Deb SP. Cell cycle regulatory functions of the
human oncoprotein MDM2. Mol Cancer Res.
2003;1(14):1009-1016.
29. McDonnell TJ, Montes de Oca Luna R, Cho S,
Amelse LL, Chavez-Reyes A, Lozano G. Loss
of one but not two mdm2 null alleles alters the
tumour spectrum in p53 null mice. J Pathol. 1999;
188(3):322-328.
30. Jones SN, Hancock AR, Vogel H, Donehower LA,
Bradley A. Overexpression of Mdm2 in mice
reveals a p53-independent role for Mdm2 in
tumorigenesis. Proc Natl Acad Sci USA. 1998;
95(26):15608-15612.
31. Barboza JA, Iwakuma T, Terzian T, El-Naggar
AK, Lozano G. Mdm2 and Mdm4 loss regulates
distinct p53 activities. Mol Cancer Res. 2008;6(6):
947-954.
32. Bond GL, Hu W, Bond EE, et al. A single
nucleotide polymorphism in the MDM2 promoter
attenuates the p53 tumor suppressor pathway
and accelerates tumor formation in humans. Cell.
2004;119(5):591-602.
33. Hu W, Feng Z, Ma L, et al. A single nucleotide
polymorphism in the MDM2 gene disrupts the
oscillation of p53 and MDM2 levels in cells.
Cancer Res. 2007;67(6):2757-2765.
34. Xu-Monette ZY, Wu L, Visco C, et al. Mutational
profile and prognostic significance of TP53 in
diffuse large B-cell lymphoma patients treated
with R-CHOP: report from an International DLBCL
Rituximab-CHOP Consortium Program Study.
Blood. 2012;120(19):3986-3996.
BLOOD, 10 OCTOBER 2013 x VOLUME 122, NUMBER 15 MDM2 PHENOTYPIC AND GENOTYPIC PROFILING IN DLBCL 2639
For personal use only.on February 13, 2017. by guest  www.bloodjournal.orgFrom 
35. Cheson BD. The International Harmonization
Project for response criteria in lymphoma clinical
trials. Hematol Oncol Clin North Am. 2007;21(5):
841-854.
36. Visco C, Li Y, Xu-Monette ZY, et al.
Comprehensive gene expression profiling and
immunohistochemical studies support application
of immunophenotypic algorithm for molecular
subtype classification in diffuse large B-cell
lymphoma: a report from the International DLBCL
Rituximab-CHOP Consortium Program Study.
Leukemia. 2012;26(9):2103-2113.
37. Gorgoulis VG, Zoumpourlis V, Rassidakis GZ,
et al. A molecular and immunohistochemical study
of the MDM2 protein isoforms and p53 gene
product in bronchogenic carcinoma. J Pathol.
1996;180(2):129-137.
38. Møller MB, Nielsen O, Pedersen NT. Frequent
alteration of MDM2 and p53 in the molecular
progression of recurring non-Hodgkin’s
lymphoma. Histopathology. 2002;41(4):322-330.
39. Rassidakis GZ, Thomaides A, Wang S, et al. p53
gene mutations are uncommon but p53 is
commonly expressed in anaplastic large-cell
lymphoma. Leukemia. 2005;19(9):1663-1669.
40. Yeudall WA, Vaughan CA, Miyazaki H, et al.
Gain-of-function mutant p53 upregulates CXC
chemokines and enhances cell migration.
Carcinogenesis. 2012;33(2):442-451.
41. Ruzov A, Shorning B, Mortusewicz O, Dunican
DS, Leonhardt H, Meehan RR. MBD4 and MLH1
are required for apoptotic induction in xDNMT1-
depleted embryos. Development. 2009;136(13):
2277-2286.
42. Lee IH, Kawai Y, Fergusson MM, et al. Atg7
modulates p53 activity to regulate cell cycle and
survival during metabolic stress. Science. 2012;
336(6078):225-228.
43. O-charoenrat P, Sarkaria I, Talbot SG, et al.
SCCRO (DCUN1D1) induces extracellular matrix
invasion by activating matrix metalloproteinase 2.
Clin Cancer Res. 2008;14(21):6780-6789.
44. Freed-Pastor WA, Prives C. Mutant p53: one
name, many proteins. Genes Dev. 2012;26(12):
1268-1286.
45. Suh YA, Post SM, Elizondo-Fraire AC, et al.
Multiple stress signals activate mutant p53 in vivo.
Cancer Res. 2011;71(23):7168-7175.
46. Inoue T, Geyer RK, Howard D, Yu ZK, Maki CG.
MDM2 can promote the ubiquitination, nuclear
export, and degradation of p53 in the absence of
direct binding. J Biol Chem. 2001;276(48):
45255-45260.
47. Lukashchuk N, Vousden KH. Ubiquitination and
degradation of mutant p53. Mol Cell Biol. 2007;
27(23):8284-8295.
48. Bittenbring J, Parisot F, Wabo A, et al. MDM2
gene SNP309 T/G and p53 gene SNP72 G/C do
not influence diffuse large B-cell non-Hodgkin
lymphoma onset or survival in central European
Caucasians. BMC Cancer. 2008;8:116.
49. Hartmann E, Ferna`ndez V, Stoecklein H,
Herna´ndez L, Campo E, Rosenwald A. Increased
MDM2 expression is associated with inferior
survival in mantle-cell lymphoma, but not related
to the MDM2 SNP309. Haematologica. 2007;
92(4):574-575.
50. Petitjean A, Mathe E, Kato S, et al. Impact
of mutant p53 functional properties on TP53
mutation patterns and tumor phenotype: lessons
from recent developments in the IARC TP53
database. Hum Mutat. 2007;28(6):622-629.
2640 XU-MONETTE et al BLOOD, 10 OCTOBER 2013 x VOLUME 122, NUMBER 15
For personal use only.on February 13, 2017. by guest  www.bloodjournal.orgFrom 
online August 27, 2013
 originally publisheddoi:10.1182/blood-2012-12-473702
2013 122: 2630-2640
 
 
A. Piris, L. Jeffrey Medeiros and Ken H. Young
Xiaoying Zhao, Carlos E. Bueso-Ramos, Sa A. Wang, Ronald S. Go, Yong Li, Jane N. Winter, Miguel
Krieken, Qin Huang, Jooryung Huh, Weiyun Ai, Maurilio Ponzoni, Andrés J. M. Ferreri, Lin Wu, 
Tam, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W. L. Choi, J. Han van
Ganiraju C. Manyam, Louise Kristensen, Lei Fan, Carlo Visco, Karen Dybkær, April Chiu, Wayne 
Zijun Y. Xu-Monette, Michael B. Møller, Alexander Tzankov, Santiago Montes-Moreno, Wenwei Hu,
 
DLBCL Rituximab-CHOP Consortium Program
rituximab-CHOP immunochemotherapy: a report from the International
status, in diffuse large B-cell lymphoma patients treated with 
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic
 
http://www.bloodjournal.org/content/122/15/2630.full.html
Updated information and services can be found at:
 (2461 articles)Lymphoid Neoplasia    
Articles on similar topics can be found in the following Blood collections
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml
Information about subscriptions and ASH membership may be found online at:
  
Copyright 2011 by The American Society of Hematology; all rights reserved.
of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society
For personal use only.on February 13, 2017. by guest  www.bloodjournal.orgFrom 
